A/S, a global healthcare company specializing in diabetes care and other chronic conditions, has been at the forefront of the rapidly expanding GLP-1 market. With a market capitalization of $376.79 ...
corporate vice president of cell therapy R&D at NovoNordisk, commented: “Cell therapy holds the promise to offer truly disease-modifying treatments for people living with serious chronic ...
Some results have been hidden because they may be inaccessible to you